LRMR Rasio cepet Larimar Therapeutics

Larimar Therapeutics (LRMR) revenue is based on the market launch of an innovative treatment for Friedreich's ataxia, while the asset's market value dynamics demonstrate the 4.53 indicator. The company is currently focusing all resources on completing the final clinical trials of its core platform. The project's success is driven by a staff of leading global experts who are provided with a modern infrastructure and reliable funding to combat rare pathologies.

The viability of Larimar Therapeutics (LRMR) depends entirely on the volume of external financing raised due to the absence of commercial products. This dependency is reflected in the ratio of cash and accounts receivable to current liabilities. This metric excludes illiquid inventories, measuring the company's ability to instantaneously settle debts without asset liquidation. By analyzing the trend of the quick ratio, an investor can assess the current margin of safety of the business's cash position.